68.87 USD
+0.46 (+0.67%)
68.87 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to HALO. HALO was compared to 530 industry peers in the Biotechnology industry. HALO has an excellent profitability rating, but there are some minor concerns on its financial health. HALO is evaluated to be cheap and growing strongly. This does not happen too often! This makes HALO very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
HALO had positive earnings in the past year.
HALO had a positive operating cash flow in the past year.
HALO had positive earnings in each of the past 5 years.
Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HALO (26.81%) is better than 97.55% of its industry peers.
With an excellent Return On Equity value of 118.17%, HALO belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
HALO's Return On Invested Capital of 42.77% is amongst the best of the industry. HALO outperforms 99.25% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 18.22%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
HALO's Profit Margin of 47.91% is amongst the best of the industry. HALO outperforms 98.11% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 59.33%, HALO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
In the last couple of years the Operating Margin of HALO has declined.
HALO's Gross Margin of 84.55% is amongst the best of the industry. HALO outperforms 87.17% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
The number of shares outstanding for HALO has been reduced compared to 1 year ago.
The number of shares outstanding for HALO has been reduced compared to 5 years ago.
HALO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.05 indicates that HALO is not in any danger for bankruptcy at the moment.
The Altman-Z score of HALO (5.05) is better than 72.83% of its industry peers.
HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.51, HALO belongs to the top of the industry, outperforming 93.21% of the companies in the same industry.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
The Debt to Equity ratio of HALO (1.59) is worse than 79.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.05 |
ROIC/WACC5.45
WACC7.85%
2.3 Liquidity
HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.59, HALO is not doing good in the industry: 81.70% of the companies in the same industry are doing better.
A Quick Ratio of 1.37 indicates that HALO should not have too much problems paying its short term obligations.
HALO has a worse Quick ratio (1.37) than 83.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.55% over the past year.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.25% yearly.
The Revenue is expected to grow by 12.82% on average over the next years. This is quite good.
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.23, the valuation of HALO can be described as correct.
96.98% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.57, HALO is valued rather cheaply.
A Price/Forward Earnings ratio of 8.30 indicates a reasonable valuation of HALO.
HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 99.06% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.04. HALO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.23 | ||
| Fwd PE | 8.3 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.79% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 97.36% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.44 | ||
| EV/EBITDA | 10.46 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
HALO's earnings are expected to grow with 31.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y31.96%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
68.87
+0.46 (+0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change15.59%
Ins Owners0.83%
Ins Owner Change-0.65%
Market Cap8.10B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts77.33
Price Target77.52 (12.56%)
Short Float %10.64%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)0.44%
PT rev (3m)6.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.57%
EPS NY rev (1m)1.91%
EPS NY rev (3m)2.25%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.23 | ||
| Fwd PE | 8.3 | ||
| P/S | 6.52 | ||
| P/FCF | 13.44 | ||
| P/OCF | 13.26 | ||
| P/B | 16.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.46 |
EPS(TTM)5.63
EY8.17%
EPS(NY)8.29
Fwd EY12.04%
FCF(TTM)5.12
FCFY7.44%
OCF(TTM)5.2
OCFY7.54%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.24
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.05 |
F-Score8
WACC7.85%
ROIC/WACC5.45
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.25%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.23 and the Price/Book (PB) ratio is 16.07.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.